☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Viatris
Viatris and Sandoz Report Results of Hulio and Hyrimoz (biosimilar, adalimumab) for the Treatment of Inflammatory Bowel Disease
August 11, 2022
Viatris and Biocon Launched Abevmy (biosimilar, bevacizumab) for the Treatment of Cancer in Canada
May 19, 2022
Insights+ Key Biosimilars Events of March 2022
April 7, 2022
Viatris and Biocon’s MYL-1402O (biosimilar, bevacizumab) Demonstrate High Similarity to Avastin in NSCLC
January 3, 2022
Viatris and Biocon’s MYL-1402O (biosimilar, bevacizumab) Demonstrate High Similarity to Avastin in NSCLC
January 3, 2022
PharmaShots Weekly Snapshots (November 15 - 19, 2021)
November 19, 2021
Load more...
Back to Home